Allegro
Description
We will be there for the pitching session, but we won't participate in one-to-one meetings.
Allegro developed the first causal treatment for osteoarthritis, based on our nanotechnology platform. Our lead asset is a crosslinked polypeptide with unique biomechanical properties, which restores the rheopectic (strength) behaviour of the synovial fluid in osteoarthritis, resulting in immediate pain relief and long term cartilage protection, even under dynamic conditions.
The MoA has been confirmed in equine models, with the clinical trials starting in 2025.
With a world class board and investors, the company is on its way to disrupt a therapeutic area that has been standstill for the last decades.
Company members
Lucas Decuypere
